高雄醫學大學圖書館 |

Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma // Huimin Zou.
作者:	Zou, Huimin,
面頁冊數:	1 electronic resource (383 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-10, Section: A.
提要註:	Background: Hepatocellular carcinoma (HCC) constitutes more than 75%-85% of primary liver cancer cases worldwide, with approximately 45% of HCC-related deaths occurring in China. This disease imposes a significant economic burden on patients, healthcare payers, and society at large, and profoundly impacts patients' quality of life (QoL). Recent advancements in immune checkpoint inhibitors (ICIs)-based therapies have shown promising improvements in survival outcomes for advanced HCC. However, there is a notable absence of comprehensive research addressing the clinical and economic outcomes of ICIs-based therapies among Chinese patients with advanced HCC. Objectives: This research aimed to (1) present a comprehensive analysis of economic and humanistic burden of HCC in greater China; (2) summarize and quantitatively evaluate the effectiveness of ICIs in treating advanced HCC patients; (3) examine indepth the structural and methodological assumptions utilized in model-based health economic evaluations concerning the systemic therapies of advanced HCC; and (4) assess the effectiveness and cost-effectiveness of ICIs-based therapies for advanced HCC.Methodology: A systematic review and meta-analysis were employed to summarize the disease burden of HCC, assess the effectiveness of ICIs, and scrutinize the structural and methodological assumptions underpinning health economic evaluations. Retrospective analysis was conducted to explore the clinical epidemiology of HCC, as well as treatment patterns and outcomes associated with ICIs-based therapies for advanced HCC. Furthermore, a modeling study utilizing a partitioned survival model was employed to gauge the cost-effectiveness of ICIs-based therapies for advanced HCC.Results: HCC has imposed a substantial economic and QoL burden on patients across greater China, escalating health-related expenses accompanying disease progression. Both physical and psychological factors have been identified as predictors of QoL among individuals with HCC. Notably, hepatitis B virus (HBV) infection has emerged as the predominant factor associated with HCC in China. Epidemiological factors such as gender, age, and ethnicity have been linked to the clinical characteristics of HBV infection, liver cirrhosis, portal vein tumor thrombus (PVTT), and BCLC stage, influencing the incidence and progression of HCC. In clinical outcomes, the utilization of first-line ICIs-based therapies in real-world practice has unveiled promising prospects. Among the most frequently employed treatment modalities, including camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE, discernible differences in patient characteristics related to gender, HBV infection, liver cirrhosis, PVTT, and BCLC stage were observed. However, while median progressionfree survival did not significantly differ among patients receiving tislelizumab, camrelizumab, and tislelizumab + TACE, objective response rates and disease control rates remained comparable across these treatment groups. On the economic front, the adoption of diverse modeling approaches and assumptions in disease modeling for health economic evaluations of systemic therapies in advanced HCC has led to considerable uncertainties in outcomes. Proposing methodological recommendations, we advocate for the utilization of an appropriate partitioned survival model, which has demonstrated the cost-effectiveness of camrelizumab plus rivoceranib compared to sorafenib as a first-line therapy for patients with unresectable HCC in the Chinese setting.Conclusion: This research provides robust evidence on the clinical and economic outcomes of ICIs-based therapies for advanced HCC. This implies that utilizing ICIs-based therapies in China could improve the management of HCC. At the same time, it is necessary to increase the accessibility and affordability of high-quality treatment options for Chinese patients with advanced HCC.
Contained By:	Dissertations Abstracts International86-10A.
標題:	Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31768880
ISBN:	9798310198821

Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma /
Zou, Huimin,

Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma /Huimin Zou. - 1 electronic resource (383 pages)

Source: Dissertations Abstracts International, Volume: 86-10, Section: A.

Background: Hepatocellular carcinoma (HCC) constitutes more than 75%-85% of primary liver cancer cases worldwide, with approximately 45% of HCC-related deaths occurring in China. This disease imposes a significant economic burden on patients, healthcare payers, and society at large, and profoundly impacts patients' quality of life (QoL). Recent advancements in immune checkpoint inhibitors (ICIs)-based therapies have shown promising improvements in survival outcomes for advanced HCC. However, there is a notable absence of comprehensive research addressing the clinical and economic outcomes of ICIs-based therapies among Chinese patients with advanced HCC. Objectives: This research aimed to (1) present a comprehensive analysis of economic and humanistic burden of HCC in greater China; (2) summarize and quantitatively evaluate the effectiveness of ICIs in treating advanced HCC patients; (3) examine indepth the structural and methodological assumptions utilized in model-based health economic evaluations concerning the systemic therapies of advanced HCC; and (4) assess the effectiveness and cost-effectiveness of ICIs-based therapies for advanced HCC.Methodology: A systematic review and meta-analysis were employed to summarize the disease burden of HCC, assess the effectiveness of ICIs, and scrutinize the structural and methodological assumptions underpinning health economic evaluations. Retrospective analysis was conducted to explore the clinical epidemiology of HCC, as well as treatment patterns and outcomes associated with ICIs-based therapies for advanced HCC. Furthermore, a modeling study utilizing a partitioned survival model was employed to gauge the cost-effectiveness of ICIs-based therapies for advanced HCC.Results: HCC has imposed a substantial economic and QoL burden on patients across greater China, escalating health-related expenses accompanying disease progression. Both physical and psychological factors have been identified as predictors of QoL among individuals with HCC. Notably, hepatitis B virus (HBV) infection has emerged as the predominant factor associated with HCC in China. Epidemiological factors such as gender, age, and ethnicity have been linked to the clinical characteristics of HBV infection, liver cirrhosis, portal vein tumor thrombus (PVTT), and BCLC stage, influencing the incidence and progression of HCC. In clinical outcomes, the utilization of first-line ICIs-based therapies in real-world practice has unveiled promising prospects. Among the most frequently employed treatment modalities, including camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE, discernible differences in patient characteristics related to gender, HBV infection, liver cirrhosis, PVTT, and BCLC stage were observed. However, while median progressionfree survival did not significantly differ among patients receiving tislelizumab, camrelizumab, and tislelizumab + TACE, objective response rates and disease control rates remained comparable across these treatment groups. On the economic front, the adoption of diverse modeling approaches and assumptions in disease modeling for health economic evaluations of systemic therapies in advanced HCC has led to considerable uncertainties in outcomes. Proposing methodological recommendations, we advocate for the utilization of an appropriate partitioned survival model, which has demonstrated the cost-effectiveness of camrelizumab plus rivoceranib compared to sorafenib as a first-line therapy for patients with unresectable HCC in the Chinese setting.Conclusion: This research provides robust evidence on the clinical and economic outcomes of ICIs-based therapies for advanced HCC. This implies that utilizing ICIs-based therapies in China could improve the management of HCC. At the same time, it is necessary to increase the accessibility and affordability of high-quality treatment options for Chinese patients with advanced HCC.

English

ISBN: 9798310198821Subjects--Topical Terms:

187040
Immunology.
Subjects--Index Terms:

China

Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma /
LDR:05528nam a22004813i 4500 001 391476
005 20251124054803.5
006 m o d
007 cr|nu||||||||
008 251208s2024 miu||||||m |||||||eng d
020 $a 9798310198821
035 $a (MiAaPQD)AAI31768880
035 $a AAI31768880
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Zou, Huimin, $e author. $3 524014
245 1 0 $a Clinical and Economic Outcomes of Immune Checkpoint Inhibitors-Based Therapies for Advanced Hepatocellular Carcinoma / $c Huimin Zou.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (383 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-10, Section: A.
500 $a Advisors: Hu, Hao; Ung, Oi Lam.
502 $b Ph.D. $c University of Macau $d 2024.
520 $a Background: Hepatocellular carcinoma (HCC) constitutes more than 75%-85% of primary liver cancer cases worldwide, with approximately 45% of HCC-related deaths occurring in China. This disease imposes a significant economic burden on patients, healthcare payers, and society at large, and profoundly impacts patients' quality of life (QoL). Recent advancements in immune checkpoint inhibitors (ICIs)-based therapies have shown promising improvements in survival outcomes for advanced HCC. However, there is a notable absence of comprehensive research addressing the clinical and economic outcomes of ICIs-based therapies among Chinese patients with advanced HCC. Objectives: This research aimed to (1) present a comprehensive analysis of economic and humanistic burden of HCC in greater China; (2) summarize and quantitatively evaluate the effectiveness of ICIs in treating advanced HCC patients; (3) examine indepth the structural and methodological assumptions utilized in model-based health economic evaluations concerning the systemic therapies of advanced HCC; and (4) assess the effectiveness and cost-effectiveness of ICIs-based therapies for advanced HCC.Methodology: A systematic review and meta-analysis were employed to summarize the disease burden of HCC, assess the effectiveness of ICIs, and scrutinize the structural and methodological assumptions underpinning health economic evaluations. Retrospective analysis was conducted to explore the clinical epidemiology of HCC, as well as treatment patterns and outcomes associated with ICIs-based therapies for advanced HCC. Furthermore, a modeling study utilizing a partitioned survival model was employed to gauge the cost-effectiveness of ICIs-based therapies for advanced HCC.Results: HCC has imposed a substantial economic and QoL burden on patients across greater China, escalating health-related expenses accompanying disease progression. Both physical and psychological factors have been identified as predictors of QoL among individuals with HCC. Notably, hepatitis B virus (HBV) infection has emerged as the predominant factor associated with HCC in China. Epidemiological factors such as gender, age, and ethnicity have been linked to the clinical characteristics of HBV infection, liver cirrhosis, portal vein tumor thrombus (PVTT), and BCLC stage, influencing the incidence and progression of HCC. In clinical outcomes, the utilization of first-line ICIs-based therapies in real-world practice has unveiled promising prospects. Among the most frequently employed treatment modalities, including camrelizumab, tislelizumab, camrelizumab + TACE, and tislelizumab + TACE, discernible differences in patient characteristics related to gender, HBV infection, liver cirrhosis, PVTT, and BCLC stage were observed. However, while median progressionfree survival did not significantly differ among patients receiving tislelizumab, camrelizumab, and tislelizumab + TACE, objective response rates and disease control rates remained comparable across these treatment groups. On the economic front, the adoption of diverse modeling approaches and assumptions in disease modeling for health economic evaluations of systemic therapies in advanced HCC has led to considerable uncertainties in outcomes. Proposing methodological recommendations, we advocate for the utilization of an appropriate partitioned survival model, which has demonstrated the cost-effectiveness of camrelizumab plus rivoceranib compared to sorafenib as a first-line therapy for patients with unresectable HCC in the Chinese setting.Conclusion: This research provides robust evidence on the clinical and economic outcomes of ICIs-based therapies for advanced HCC. This implies that utilizing ICIs-based therapies in China could improve the management of HCC. At the same time, it is necessary to increase the accessibility and affordability of high-quality treatment options for Chinese patients with advanced HCC.
546 $a English
590 $a School code: 1382
650 4 $2 96060 $a Immunology. $3 187040
650 4 $a Gender studies. $3 523799
650 4 $2 96060 $a Oncology. $3 273823
650 4 $2 96060 $a Public health. $3 206087
650 4 $2 96060 $a Biomedical engineering. $3 243441
653 $a China
653 $a Disease modelling
653 $a Hepatocellular carcinoma
653 $a Immune checkpoint inhibitors
653 $a Retrospective analysis
653 $a Systematic review
690 $a 0541
690 $a 0992
690 $a 0982
690 $a 0733
690 $a 0573
710 2 $a University of Macau. $b Chinese Medical Sciences. $e degree granting institution. $3 524015
720 1 $a Hu, Hao $e degree supervisor.
720 1 $a Ung, Oi Lam $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-10A.
790 $a 1382
791 $a Ph.D.
792 $a 2024
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31768880